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Multidrug resistance has become a factor seri-
ously limiting treatment of various diseases, includ-
ing bacterial (1ñ3) and fungal (4) infections and can-
cer (5ñ7). The major mechanism of multidrug resist-
ance (MDR) in cancer is the over-expression of
ATP-dependent drug-efflux pumps (drug trans-
porters), which reduces the accumulation of agents.
One of the most important mechanisms of MDR in
cancer is the over-expression of ABC multidrug
transporters, e.g., P-glycoprotein (P-gp, ABCB1).
Various chemical groups possessing efflux pump
inhibitor (EPI) properties in P-gp have been
described (7ñ9), including three generations of P-gp
modulators, but none of them has passed the phase
of clinical trials because of the undesirable side
effects (5). Consequently, it is a big challenge to
search for new successful P-gp inhibitors which are
active during chemotherapy and produce minimal
side effects. 
In this context, our interest has been focused on
potential EPI activity of arylidene(thio)hydantoin
derivatives. Particularly, as recent lines of evidence
distinctly identified and described a presence of ben-
zyl-hydantoin binding site in protein transporters
(10, 11). Recently, there is an increasing interest in
hydantoin derivatives as potential anticancer agents
(12ñ14). It has been shown that hydantoin deriva-
tives inhibit autophosphorylation and proliferation
of some human cancer cells that over-express EGFR
(12, 13). Furthermore, phenylmethylene-hydantoins
with anti-metastatic activity were described as well
(14).
Derivatives of (thio)hydantoin are one of our
main interests for more than twenty years. Our pre-
vious works described a number of aromatic hydan-
toin derivatives which demonstrated various phar-
macological properties as antimicrobial (15ñ17),
hypotensive, antiarrhythmic- or/and GPCR-agents
5-ARYLIDENE(THIO)HYDANTOIN DERIVATIVES AS MODULATORS 
OF CANCER EFFLUX PUMP*
JADWIGA HANDZLIK1**, GABRIELLA SPENGLER2, BEATA MASTEK1, ANNA DELA1, JOSEPH
MOLNAR2, LEONARD AMARAL3 and KATARZYNA KIE∆-KONONOWICZ1
1Faculty of Pharmacy, Jagiellonian University, Medical College, Medyczna 9, 30-688 KrakÛw, Poland;
2Institute of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, 
Szeged, Hungary
3Unit of Mycobacteriology, Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa
(IHMT/UNL), Lisbon, Portugal and Cost Action BM0701 of the European Commission
Keywords: arylidenethiohydantoin, arylideneimidazolones, piperazine, cancer cells, P-glycoprotein (ABCB1)
modulators
149
* The 2nd Place Award in the Young Scientists Presentations Competition during the IVth Conversatory on Medicinal Chemistry, 8-10.
09. 2011, Lublin, Poland
** Corresponding author: jhandzli@cm-uj.krakow.pl
Figure 1. Compounds with confirmed P-gp inhibiting properties
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(18ñ20). Our recent studies (21) indicated that some
arylidene(thio)hydantoin derivatives (Fig.1, 1 and 2)
possessed P-gp modulating properties in cancer cells
in the range of verapamil or higher (Fig. 1). It sug-
gested that further studies on arylidenehydantoin
derivatives as modulators of MDR efflux pumps of
cancer cells should be performed. Thus, the present
work is focused on derivatives of thiohydantoin: 5-
arylideneimidazolones with piperazine substituent.
A series of new hydroxyethylpiperazine aryli-
deneimidazolone derivatives 3ñ9 (Fig. 2) were syn-
thesized and tested on their efflux modulating
effects in T-lymphoma cancer cells as well as struc-
ture-activity relationship was analyzed.
EXPERIMENTAL
Chemistry
1H-NMR spectra were recorded on a Varian
Mercury VX 300 MHz PFG instrument (Varian Inc.,
Palo Alto, CA, USA) in DMSO-d6 at ambient tem-
perature using the solvent signal as an internal stan-
dard. IR spectra were recorded on a Jasco FT/IR-410
apparatus using KBr pellets and are reported in cmñ1.
Thin-layer chromatography was performed on pre-
coated Merck silica gel 60 F254 aluminium sheets, the
used solvent systems were: (I) chloroform/iso-
propanol/NH3 9:11:3; (II) methylene chloride/
methanol (1:1, v/v). Melting points were determined
using Mel-Temp II apparatus and are uncorrected.
Elemental analyses were within ± 0.4% of the theo-
retical values unless stated otherwise. Syntheses
under microwave irradiation were performed in
household microwave oven Samsung M1618.
Methods of synthesis of compounds 11-24 were per-
formed according to the methods described earlier
(15ñ17).
General method for synthesis of compounds 3ñ9
1-(2-Hydroxyethyl)piperazine (10 mmol, 1.30
g) and a suitable 2-(methylthio)-5-arylidene-1H-
imidazol-4(5H)-on 18ñ24 (5 mmol) were put into
roumd bottom flask and melted at 110ñ130∞C on oil
bath under reflux linked to an absorber with concen-
trated HNO3. The melting was continued for 40ñ90
min. Then, ethanol (10ñ15 mL) was added and the
mixture was refluxed for 5ñ6 h. The mixture was left
at room temperature overnight. The precipitate of
products 3bñ9b was separated by filtration, washed
with ethanol, purified by crystallization with ethanol
or by column chromatography. Compounds in basic
form 3bñ9b were suspended in dry ethanol (10 mL)
and saturated with gaseous HCl to give correspon-
ding hydrochlorides 3ñ9.
Synthesis of (Z)-5-benzylidene-2-(4-(2-hydroxy-
ethyl)piperazin-1-yl)-1H-imidazol-4(5H)-one
hydrochloride (3)
(Z)-5-benzylidene-2-(4-(2-hydroxyethyl)piperazin-
1-yl)-1H-imidazol-4(5H)-one (3b)
1-(2-Hydroxyethyl)piperazine with (Z)-5-ben-
zylidene-2-(methylthio)-1H-imidazol-4(5H)-one 18
(5 mmol, 1.09 g) were melted at 120OC for 60 min.
The mixture with ethanol (10 mL) was stirred and
refluxed for 6 h. Pure white-grey crystals of product
3b were obtained after filtration (3 mmol, 0.95 g,
Cpd. Ar Cpd. Ar
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Figure 2. Arylidene-imidazolone derivatives 3ñ9
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63%); m.p. 204ñ207OC; Rf (I) 0.41. 1H-NMR
(DMSO-d6, δ, ppm): 2.44 (t, J = 6.16 Hz, 2H, Pp-
CH2), 2.48ñ2.51 (m, 4H, Pp-3,5-H), 3.48ñ3.54 (m,
4H, Pp-2,6-H), 3.58 (br s, 2H, CH2-OH), 4.42 (t, J =
5.20 Hz, 1H, OH), 6.29 (s, 1H, CH=C), 7.18ñ7.23 (t
def., 1H, Ar-4-H), 7.31ñ7.36 (t def., 2H, Ar-3,5-H),
8.00 (br s, 2H, Ar-2,6-H), 11.25 (br. s, 1H, NH).
(Z)-5-benzylidene-2-(4-(2-hydroxyethyl)piperazin-
1-yl)-1H-imidazol-4(5H)-one hydrochloride (3)
Compound 3b (0.86 mmol, 0.257 g) in dry
ethanol (6 mL) was converted into hydrochloride to
give white powder of 3 (0.64 mmol, 0.24 g, 75%);
m.p. 255ñ260OC; Rf (I) 0.41. Analysis: calcd. for
C16H20N4O2 ◊ 1.75 HCl ◊ 0.5 H2O: C, 51.50; H, 6.14;
N, 15.01%; found: C, 51.60; H, 5.83 ; N, 15.17%.
Synthesis of (Z)-5-(4-chlorobenzylidene)-2-(4-(2-
hydroxyethyl)piperazin-1-yl)-1H-imidazol-4(5H)
-one hydrochloride (4)
(Z)-5-(4-chlorobenzylidene)-2-(4-(2-hydrox-
yethyl)piperazin-1-yl)-1H-imidazol-4(5H)-one (4b)
1-(2-Hydroxyethyl)piperazine and (Z)-5-(4-
chlorobenzylidene)-2-(methylthio)-1H-imidazol-
4(5H)-one 19 (5 mmol, 1.26 g) were melted at
120∞C for 90 min. The mixture with ethanol (10 mL)
was stirred and refluxed for 5.5 h. Pure yellow crys-
tals of product 4b was obtained (2 mmol, 0.61g,
36%); m.p. 197ñ199OC; Rf (I) 0.48. 1H-NMR
(DMSO-d6, δ, ppm): 2.41 (t, J = 6.61 Hz, 2H, Pp-
CH2), 2.48 (dd, J1 = 3.85 Hz, J2 = 1.80 Hz, 4H, Pp-
3,5-H), 3.49 (dd, J1 = 11.28 Hz, J2 = 5.90 Hz, 2H,
CH2-OH), 3.59 (br. s, 4H, Pp-2,6-H), 4.42ñ4.45 (t
def., 1H, OH), 6.27 (s, 1H, CH=C), 7.37 (d, J = 8.46
Hz, 2H, Ar-3,5-H), 8.02(d, J = 7.44 Hz, 2H, Ar-2,4-
H), 11.28 (br. s, 1H, N1-H).
(Z)-5-(4-chlorobenzylidene)-2-(4-(2-hydrox-
yethyl)piperazin-1-yl)-1H-imidazol-4(5H)-one
hydrochloride (4)
Compound 4b (0.93 mmol, 0.31 g) in dry
ethanol (6 mL) was converted into hydrochloride to
give white powder of 4 (0.90 mmol, 0.36 g , 98%);
m.p. 263ñ265OC; Rf (I) 0.48. Analysis: calcd. for
C16H19N4O2Cl ◊ HCl ◊ 1.5 H2O: C, 48.25; H, 5.82; N,
14.07%; found: C, 48.59; H, 5.82; N, 14.03%. 1H-
NMR (DMSO-d6, δ, ppm): 3.19 (br s, 4H, Pp-2,6-H),
3.56ñ3.64 (t def., 5H, Pp-3,5-H, Pp-CH2a), 3.77ñ3.81
(t def., 3H, Pp-CH2b, CH2-OH), 4.31 (br. s, 1H, OH),
6.43 (s, 1H, CH=C), 7.39ñ7.50 (dt def., 2H, Ar-3,5-
H), 8.03 (d, J = 8.72 Hz, 2H, Ar-2,4-H), 10.82 (br. s,
1H, N1-H). IR (KBr, cm-1): 3343 (N1-H), 2997 (OH),
2939 (CH), 2850 (C-CH2-C), 2633 (NH+), 1761
(C=O), 1686 (Ar-CH=H), 1602 (Ar, C=C).
Synthesis of (Z)-5-(3-chlorobenzylidene)-2-(4-(2-
hydroxyethyl)piperazin-1-yl)-1H-imidazol-
4(5H)-one hydrochloride (5)
(Z)-5-(3-chlorobenzylidene)-2-(4-(2-hydrox-
yethyl)piperazin-1-yl)-1H-imidazol-4(5H)-one (5b )
1-(2-Hydroxyethyl)piperazine and (Z)-5-(3-
chlorobenzylidene)-2-(methylthio)-1H-imidazol-
4(5H)-one (5 mmol, 1.26 g) were melted at 130∞C
for 60 min. The mixture with ethanol (10 mL) was
stirred and refluxed for 5 h. Pure yellow crystals of
product 5b was obtained (0.8 mmol, 0.27g, 16%);
m.p. 183ñ184OC; Rf (I) 0.39. 1H-NMR (DMSO-d6,
δ, ppm): 2.41ñ2.52 (m, 6H, Pp-3,5-H, Pp-CH2),
3.49ñ3.69 (m, 6H, Pp-2,6-H, CH2-OH), 4.42 (t, J =
5.39 Hz, 1H, OH), 6.26 (s, 1H, CH=C), 7.22ñ7.25 (d
def., 1H, Ar-4-H), 7.32ñ7.38 (t def., 1H, Ar-5-H),
7.91ñ7.93 (d def., 1H, Ar-6-H), 8.17 (br s, 1H, Ar-
2-H), 11.34 (br s, 1H, N1-H).
(Z)-5-(3-chlorobenzylidene)-2-(4-(2-hydrox-
yethyl)piperazin-1-yl)-1H-imidazol-4(5H)-one
hydrochloride (5)
Compound 5b (0.6 mmol, 0.20 g) in dry
ethanol (6 mL) was converted into hydrochloride to
give yellow powder of 5 (0.35 mmol, 0.13 g , 58%);
m.p. 253ñ255OC; Rf (I) 0.39. Analysis: calcd. for
C16H20N4O2 ◊ HCl ◊ 0.25 H2O: C, 51.14; H, 5.50; N,
14.91%; found: C, 51.03; H, 5.50; N, 14.64. 1H-
NMR (DMSO-d6, δ, ppm): 3.19 (s, 2H, Pp-CH2),
3.39ñ3.43(t def., 4H, Pp-3,5-H), 3.60 (s def., 4H,
Pp-2,6-H), 3.76ñ3.80 (t def., 2H, CH2-OH), 4.28 (br
s, 1H, OH), 6.38 (s, 1H, CH=C), 7.26 (d def., J =
8.98 Hz, 1H, Ar-4-H), 7.34-7.39 (t def., 1H, Ar-5-
H), 7.95 (d, J = 7.69 Hz, 1H, Ar-6-H), 8.14 (s, 1H,
Ar-2-H), 10.60 (br s, 1H, N1-H), 11.58 (br s, 1H,
NH+). IR (KBr, cm-1): 3303 (N1-H), 3114 (OH), 3045
(CH), 2851 (C-CH2-C), 2464 (NH+), 1706 (C=O),
1653 (Ar-CH=H), 1580 (Ar, C=C).
Synthesis of (Z)-5-(2-chlorobenzylidene)-2-(4-(2-
hydroxyethyl)piperazin-1-yl)-1H-imidazol-4(5H)
-one hydrochloride (6)
(Z)-5-(2-chlorobenzylidene)-2-(4-(2-hydrox-
yethyl)piperazin-1-yl)-1H-imidazol-4(5H)-one (6b)
1-(2-Hydroxyethyl)piperazine and (Z)-5-(2-
chlorobenzylidene)-2-(methylthio)-1H-imidazol-
4(5H)-one (5 mmol, 1.26 g) were melted at 130∞C
for 60 min. The mixture with ethanol (10 mL) was
stirred and refluxed for 5 h. Pure yellow crystals of
6b were obtained (4 mmol, 1.41g, 80%); m.p.
237ñ238OC; Rf (I) 0.43. 1H-NMR (DMSO-d6, δ,
ppm): 2.40 (t, J = 6.16 Hz, 2H, Pp-CH2),
2.48ñ2.52(m, 4H, Pp-3,5-H), 3.52 (br s, 2H, CH2-
OH), 3.69 (br s, 4H, Pp-2,6-H), 4.45 (br s, 1H, OH),
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6.58 (s, 1H, CH=C), 7.18ñ7.24 (m, 1H, Ar-4-H),
7.32ñ7.37 (m, 1H, Ar-5-H), 7.42ñ7.45 (m, 1H, Ar-
3-H), 8.79 (br s, 1H, Ar-6-H), 11.35 (br s, 1H, NH).
(Z)-5-(2-chlorobenzylidene)-2-(4-(2-hydroxy-
ethyl)piperazin-1-yl)-1H-imidazol-4(5H)-one
hydrochloride (6)
Compound 6b (1.22 mmol, 0.41 g) in dry
ethanol (7 mL) was converted into hydrochloride to
give bright powder of 6 (0.93 mmol, 0.38 g, 76%);
m.p. 230ñ233OC; Rf (I) 0.43. Analysis: calcd. for
C16H19ClN4O2 ◊ 2HCl: C, 47.13; H, 5.19; N, 13.74%;
found: C, 47.15; H, 4.94; N, 13.76%. 1H-NMR
(DMSO-d6, δ, ppm): 3.19 (br s, 4H, Pp-3,5-H),
3.61ñ3.64 (m, 5H, Pp-2,6-H, Pp-CH2a), 3.71ñ3.81 (t
def., 3H, Pp-CH2b, CH2-OH), 4.35 (br s, 1H, OH),
6.70 (s, 1H, CH=C), 7.24ñ7.30 (m, 1H, Ar-4-H),
7.34ñ7.39 (m, 1H, Ar-5-H), 7.46ñ7.49 (m, 1H, Ar-
3-H), 8.66 (d, J = 7.70 Hz, 1H, Ar-6-H), 10.90 (br s,
1H, N1-H). IR (KBr, cm-1): 3416 (N1-H), 3307 (OH),
3019 (CH), 2931 (C-CH2-C), 2685 (NH+), 1759
(C=O), 1684 (Ar-CH=H), 1605 (Ar, C=C).
Synthesis of (Z)-5-(2,4-dichlorobenzylidene)-2-(4-
(2-hydroxyethyl)piperazin-1-yl)-1H-imidazol-
4(5H)-one hydrochloride (7)
(Z)-5-(2,4-dichlorobenzylidene)-2-(4-(2-hydrox-
yethyl)piperazin-1-yl)-1H-imidazol-4(5H)-one (7b)
1-(2-Hydroxyethyl)piperazine and (Z)-5-(2,4-
dichlorobenzylidene)-2-(methylthio)-1H-imidazol-
4(5H)-one (5 mmol, 1.44 g) were melted at 130∞C
for 40 min. The mixture with ethanol (10 mL) was
stirred and refluxed for 5 h. Pure yellow crystals of
product 7b was obtained (4 mmol, 1.48 g, 80%);
m.p. 210ñ213OC; Rf (I) 0.31. 1H-NMR (DMSO-d6,
δ, ppm): 2.41 (t, J = 6.16 Hz, 2H, Pp-CH2),
2.47ñ2.52 (m, 4H, Pp-3,5-H), 3.51 (br s, 4H, Pp-2,6-
H), 3.61 (br s, 2H, CH2-OH), 4.45 (br s, 1H, OH),
6.49 (s, 1H, CH=C), 7.41ñ7.44 (dd def., 1H, Ar-5-
H), 7.58 (s, 1H, Ar-3-H), 8.80 (d, J = 7.95 Hz, 1H,
Ar-6-H), 11.41 (br s, 1H, N1-H).
(Z)-5-(2,4-dichlorobenzylidene)-2-(4-(2-hydrox-
yethyl)piperazin-1-yl)-1H-imidazol-4(5H)-one
hydrochloride (7)
Compound 7b (0.69 mmol, 0.26 g) in dry
ethanol (6 mL) was converted into hydrochloride to
give yellow powder of 7 (0.54 mmol, 0.24 g, 78%);
m.p. 235ñ240OC; Rf (I) 0.31. Analysis: calcd. for
C16H18Cl2N4O2 ◊ 1.75 HCl ◊ 0.5 H2O: C, 43.47; H,
4.73; N, 12.67%; found: C, 43.49; H, 4.73; N,
12.43%. 1H-NMR (DMSO-d6, δ, ppm): 3.19 (br s,
4H, Pp-3,5-H), 3.60ñ3.64 (d def., 5H, Pp-CH2a, Pp-
2,4-H), 3.78 (t, J = 5.10 Hz, 3H, Pp-CH2b, CH2-OH),
4.38 (br s, 1H, OH), 6.61 (s, 1H, CH=C), 7.41ñ7.44
(dd def., 1H, Ar-5-H), 7.63 (s, 1H, Ar-3-H), 8.73 (d,
J = 8.70 Hz, 1H, Ar-6-H), 10.89 (br s, 1H, N1-H). IR
(KBr, cm-1): 3321 (N1-H), 3002 (OH), 2936 (CH),
2800 (C-CH2-C), 2633 (NH+), 1764 (C=O), 1683
(Ar-CH=H), 1579 (Ar, C=C).
Synthesis of (Z)-5-(4-nitrobenzylidene)-2-(4-(2-
hydroxyethyl)piperazin-1-yl)-1H-imidazol-
4(5H)-one hydrochloride (8)
( Z ) - 5 - ( 4 - n i t r o b e n z y l i d e n e ) - 2 - ( 4 - ( 2 -
hydroxyethyl)piperazin-1-yl)-1H-imidazol-4(5H)-
one (8b)
1-(2-Hydroxyethyl)piperazine and (Z)-5-(4-
nitrobenzylidene)-2-(methylthio)-1H-imidazol-
4(5H)-one (5 mmol, 1.32 g) were melted at 110∞C
for 60 min. The mixture with ethanol (15 mL) was
stirred and refluxed for 5.5 h. Pure orange crystals of
8b were obtained (4 mmol, 1.43 g, 80%); m.p.
224ñ226OC; Rf (I) 0.30. 1H-NMR (DMSO-d6, δ,
ppm): 2.42 (t, J = 6.16 Hz, 2H, Pp-CH2), 2.47ñ2.53
(m, 4H, Pp-3,5-H), 3.50 (t, J = 6.16 Hz, 2H, CH2-
OH), 3.65 (br s, 4H, Pp-2,6-H), 4.43 (br s, 1H, OH)
6.33 (s, 1H, CH=C), 8.14ñ8.17 (d def., 2H, Ar-2,6-
H), 8.23ñ8.26 (d def., 2H, Ar-3,5-H), 11.47 (br s,
1H, N1-H).
(Z)-5-(4-nitrobenzylidene)-2-(4-(2-hydroxyeth-
yl)piperazin-1-yl)-1H-imidazol-4(5H)-one hydro-
chloride (8)
Compound 8b (0.75 mmol, 0.26 g) in dry
ethanol (6 mL) was converted into hydrochloride to
give orange powder of 8 (0.55 mmol, 0.23 g , 73%);
m.p. 272ñ275OC; Rf (I) 0.30. Analysis: calcd. for
C16H19N5O4 ◊ 2HCl: C, 45.94; H, 5.06; N, 16.74%;
found: C, 46.02; H, 4.87; N, 16.59%. 1H-NMR
(DMSO-d6, δ, ppm): 3.21 (br s, 4H, Pp-3,5-H),
3.62ñ3.66 (m, 5H, Pp-CH2a, Pp-2,6-H), 3.79ñ3.82 (t
def., 3H, Pp-CH2b, CH2-OH), 4.50 (br s, 1H, OH)
6.47 (s, 1H, CH=C), 8.15ñ8.29 (m, 4H, Ar), 10.97
(br s, 1H, N1-H). IR (KBr, cm-1): 3266 (N1-H), 3107
(OH), 2998 (CH), 2933 (C-CH2-C), 2683 (NH+),
1761 (C=O), 1686 (Ar-CH=H), 1662 (Ar, C=C).
Synthesis of (Z)-2-(4-(2-hydroxyethyl)piperazin-
1-yl)-5-(naphthalen-2-ylmethylene)-1H-imidazol-
4(5H)-one hydrochloride (9)
(Z)-2-(4-(2-hydroxyethyl)piperazin-1-yl)-5-(naph-
thalen-2-ylmethylene)-1H-imidazol-4(5H)-one (9b)
1-(2-Hydroxyethyl)piperazine and (Z)-5-(4-
nitrobenzylidene)-2-(methylthio)-1H-imidazol-
4(5H)-one (5 mmol, 1.342 g) were melted at 120OC
for 60 min. The mixture with ethanol (10 mL) was
stirred and refluxed for 5.5 h. Column chromatogra-
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phy using solvent (II) gave pure yellow crystals of
product 9b (2 mmol, 0.82 g, 47%); m.p. 306ñ308OC;
Rf (I) 0.29. 1H-NMR (DMSO-d6, δ, ppm): 3.18ñ3.34
(m, 4H, Pp-3,5-H), 3.60 (d, J = 9.75 Hz, 5H, Pp-2,6-
H, Pp-CH2a), 3.80 (br s, 3H, Pp-CH2b, CH2-OH),
4.35 (br s, 1H, OH), 7.15 (s, 1H, CH=C), 7.51ñ7.59
(m, 3H, naphth-4,5,9-H), 7.83ñ7.97 (dt def., 2H,
naphth-3,6-H), 8.22 (br s, 1H, naphth-10-H), 8.90
(br s, 1H, naphth-8-H), 11.07 (br s, 1H, N1-H).
(Z)-2-(4-(2-hydroxyethyl)piperazin-1-yl)-5-(naph-
thalen-2-ylmethylene)-1H-imidazol-4(5H)-one
hydrochloride (9)
Compound 9b (1.43 mmol, 0.500 g) in dry
ethanol (8 mL) was converted into hydrochloride to
give orange powder of 9 (1.13 mmol, 0.48 g , 80%);
m.p. 285ñ287OC; Rf (I) 0.29. Analysis: calcd. for
C20H22N4O2 ◊ 1.5 HCl ◊ H2O: C, 56.77; H, 6.07; N,
13.24%; found: C, 57.01; H, 6.33; N, 13.01%. 1H-
NMR (DMSO-d6, δ, ppm): 3.19 (br s, 4H, Pp-3,5-
H), 3.63ñ3.71 (t def., 5H, Pp-2,6-H, Pp-CH2a),
3.79ñ3.82 (t def., 3H, Pp-CH2b, CH2-OH), 4.39 (br s,
1H, OH), 7.24 (s, 1H, CH=C), 7.53ñ7.62 (m, 2H,
naphth-3,6-H), 7.89ñ7.98 (q def., 1H, naphth-10-H),
8.51 (br s, 1H, naphth-8-H), 11.29 (br s, 1H, N1-H).
IR (KBr, cm-1): 3415 (N1-H), 3312 (OH), 2997 (CH),
2661 (C-CH2-C), 2450 (NH+), 1758 (C=O), 1681
(Ar-CH=H), 1590 (Ar, C=C).
PHARMACOLOGY
Cell lines
L5178Y mouse T-cell lymphoma cells
(ECACC cat. no. 87111908, U.S. FDA, Silver
Spring, MD, USA) were transfected with pHa
MDR1/A retrovirus, as described elsewhere (22,
23).
The ABCB1-expressing cell lines were selected
by culturing the infected cells with 60 ng/mL of
colchicine (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany) to maintain the MDR pheno-
type. L5178 mouse T-cell lymphoma cells (parental)
and the human ABCB1-gene transfected sub-line
were cultured in McCoyís 5A medium (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany). sup-
plemented with 10% heat-inactivated horse serum,
L-glutamine and antibiotics (penicillin, strepto-
mycin) at 37OC and in a 5% CO2 atmosphere. 
Flow cytometry assay for evaluation of a com-
pound on the retention of rhodamine 123 by
MDR in tumor cells.
This assay has been fully described previously
(24). Briefly, the cells were adjusted to a density of
2◊106/mL, re-suspended in serum-free McCoyís 5A
medium and distributed in 0.5 mL aliquots into
Eppendorf centrifuge tubes. Volumes of 2ñ20 µL of
Scheme 1. Synthetic way: (1) Knoevenagel condensation; (2) S-methylation; (3) substitution with hydroxyethylpiperazine; (4) convertion
into hydrochlorides 3ñ9 with gaseous HCl
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test compounds were added at various concentra-
tions, and the samples were incubated for 10 min at
room temperature. Next, 10 µL (5.2 mM final con-
centration) of rhodamine 123 was added to the sam-
ples and the cells were incubated for a further 20
min at 37OC, washed twice and re-suspended in 0.5
mL of phosphate-buffered saline (PBS) for analy-
sis. The fluorescence uptake of the cell population
Figure 3. Fluorescence activity ratios (FARs) for compounds 3ñ9 in comparison to verapamil (tested at dose of 10 Ïg/mL) using rhodamine
123 accumulation assay
Figure 4. Pharmacophore hypotheses for efflux modulators in mouse T-lymphoma cells overexpressing the ABCB1 system
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was measured with FACStar Plus flow cytometer
(Beckton, Dickinson and Company, Franklin
Lakes, NJ, USA). Verapamil was used as a positive
control in the rhodamine 123 exclusion experi-
ments. The percentage mean fluorescence intensity
was calculated for the treated MDR and parental
cell lines as compared to untreated cells. A fluores-
cence activity ratio (FAR) was calculated on the
basis of the measured fluorescence values via the
following equation:
MDR treated/MDR control
FAR = ññññññññññññññññññññññññññññ
parental treated/parental control
The results presented are obtained from a rep-
resentative flow cytometry experiment in which
10,000 individual cells of the population were eval-
uated for amount of rhodamine 123 retained. They
were originally presented by the Beckton Dickinson
FACStar flow cytometer as histograms and the data
were converted to FAR units that define fluores-
cence intensity, standard deviation, peak channel in
the total- and in the gated- populations .
RESULTS
Compounds 3ñ9 were obtained within 3-step
synthesis according to the Scheme 1. In the first
step, 5-arylidene-2-thiohydantoins 11ñ17 were syn-
thesized using two variants of Knoevenagelís con-
densation for 2-thiohydantoin with suitable aromat-
ic aldehydes that was described in previous works
(15ñ17). Compounds 11ñ17 were methylated in the
second step to give intermediates 18ñ24 (15ñ17).
Final products in basic form (3bñ9b) were obtained
by the replacement of S-methyl group with hydroxy-
ethylpiperazine. The process was performed by
melting of intermediates 18ñ24 with hydroxy-
ethylpiperazine on oil-bath by the use of 2-fold
excess of the amine. Compounds 3bñ9b were sus-
pended in ethanol and converted into hydrochlorides
3ñ9 by the use of gaseous HCl (21, 22). 
Compounds 3ñ9 were tested for their efflux
modulating effects in mouse T-lymphoma cells with
over-expressed ABCB1 system using fluorescence
activated cell sorting. The modulation of intracellu-
lar drug accumulation was evaluated by flow
cytometry using rhodamine 123 accumulation assay
according to the method described previously (5, 6).
Results are presented in Figure 3.
Structure-activity relationship was analyzed
basing on chemical features of both, potential (3ñ9)
and confirmed (1, 2 and verapamil) modulators of
PgP. The following features, important for ligand-
protein interactions, were considered: aromatic moi-
ety with(out) hydrophobic substituent (Ar), hydro-
gen bond acceptor (HBA), positive ionizable center
(PI), hydrophilic moiety (HYL) as well as alkyl link-
ers which influence conformational flexibility of lig-
ands (Figure 4).
DISCUSSION AND CONCLUSION
Compounds 3ñ9 displayed weak cancer efflux
pump inhibitors properties, weaker than those of
verapamil and compound 2 and much weaker than
that of compound 1 (24). Among the new com-
pounds, compound 7 was the most promising one,
showing dose-dependent fluorescence activity ratio
(FAR), with a maximum FAR value of 1.73 at 40
µg/mL. Concerning compounds 3ñ6 and 8, 9 the
increase of concentration caused very low increase-
(4, 6, 8 and 9) or some decrease (3 and 5) of FAR.
Compounds with the highest efflux pump inhibitors
potency include two aromatic fragments Ar (Model
I and II, Fig. 4). Pharmacophore features PI, HBA
and alkyl linker(s) seem to be profitable for EPI
activity but their influence is not very strong.
Hydrophilic hydroxyl group (HYL), occurring in
compounds 3ñ9, is probably a main factor, which
decreased their activity comparing to that of com-
pounds 1, 2 and verapamil. A conversion of hydan-
toin moiety into imidazolone as well as an exchange
of amine-alkyl substituent place from position 3 into
position 2 is supposed to be an additional factor lim-
iting the activity. 
The highest activity among 5-arylideneimida-
zolones 3-9 was observed for 2,4-dichlorobenzyli-
dene derivative 7 which includes the most lipophilic
aromatic fragment (two chlorides at phenyl ring).
These results confirm an important role of
hydrophobic aromatic fragments for cancer efflux
pumps modulator properties.
Results of our study indicated that hydrophobic
aromatic moieties (Ar) were the most favorable fea-
tures for cancer EPIs activity, whereas hydrophilic
hydroxyl groups (HYL) caused a significant
decrease of the activity.
Acknowledgments
G. Spengler was supported by T¡MOP-
4.2.1/B-09/1/KONV-2010-0005 ñ Creating the
Center of Excellence at the University of Szeged
supported by the European Union and co-financed
by the European Regional Fund.
L. Amaral was supported by BCC grant
SFRH/BCC/51099/2010 provided by the ìFundaÁo
para a Cincia e a Tecnologiaî (FCT) of Portugal
156 JADWIGA HANDZLIK et al.
and PTDC/SAU-FCF/102807/2008 and by the
UPMM. This work was supported by EU-
FSE/FEDER-PTDC/BIA-MIC/105509/2008 and
EU-FSE/FEDERPTDC/SAU-FCF/102807/2008
from the ìFundaÁ„o para a CiÍncia e a Tecnologiaî
(FCT) of Portugal. 
This work was supported by the Szeged
Foundation for Cancer Research.
Synthesis was supported by Program
K/ZDS/001915 and 501/N-COST/2009/0; COST
action BM0701 (K/PMN/000031).
REFERENCES
1. Saidijam M., Benedetti G., Ren Q., Xu Z.,
Hoyle C.J., Palmer S.L., Ward A.et al.: Curr.
Drug Targets 7, 793 (2006).
2. Pags J.M., Amaral L.: Biochim. Biophys. Acta
1794, 826 (2009).
3. Pags J.M., Alibert-Franco S., Mahamoud A.,
Bolla J.M., Davin-Regli A., Chevalier J.,
Garnotel E.: Curr. Top. Med. Chem. 10, 1848
(2010).
4. Gulshan K., Moye-Rowley S.: Eucariot. Cell 6,
1933 (2007).
5. Nobili S., Landini I., Giglioni B., Mini E.: Curr.
Drugs Targets 7, 861 (2006).
6. Stavrovskaya A.A., Stromskaya T.P.:
Biochemistry 73, 592 (2008).
7. Teodori E., Dei S., Scapecchi S., Gualtieri F.:
Farmaco 57, 385 (2002).
8. Zdrazil B., Kaiser D., Kopp S., Chiba P., Ecker
G.F.: QSAR Comb. Sci. 26, 669 (2007).
9. Reyes C.P., Munoz-Mart˝nez F., Torrecillas
I.R., Mendoza C.R., Gamarro F., Bazzocchi
I.L., Nunez M.J. et al.: J. Med. Chem. 50, 4808
(2007).
10. Weyand S., Shimamura T., Yajima S., Suzuki
S., Mirza O., Krusong K., Carpenter E.P. et al.:
Science 332, 709 (2008).
11. Weyand S., Shimamura T., Beckstein O.,
Sansom M.S.P., Iwata S., Henderson P.J.F.,
Cameron A.D.: J. Synchrotron Rad. 18, 20
(2011).
12. Carmi C., Cavazzoni A., Zuliani V., Lodola A.,
Bordi F., Plazzi P.V., Alfieri R.R. et al.: Bioorg.
Med. Chem. Lett. 16, 4021 (2006).
13. Zuliani V., Carmi C., Rivara M., Fantini M.,
Lodola A., Vacondio F., Bordi F. et al.: Eur. J.
Med. Chem. 44, 3471 (2009).
14. Mudit M., Khanfar M., Muralidharan A.,
Thomas S., Shah G.V., van Soest R.W., El
Sayed K.A.: Bioorg. Med. Chem. 17, 1731
(2009) Erratum in: Bioorg. Med. Chem. 17,
3216 (2009). 
15. KieÊ-Kononowicz K., SzymaÒska E.: Farmaco
57, 909 (2002).
16. KieÊ-Kononowicz K., SzymaÒska E., Motyl M.,
Holzer W., Bia≥ecka A., Kasprowicz A.:
Pharmazie 53, 680 (1998).
17. SzymaÒska E., KieÊ-Kononowicz K.: Farmaco
57, 355 (2002). 
18. Dylπg T., Zygmunt M., Maciπg D., Handzlik J.,
Bednarski M., Filipek B., KieÊ-
Kononowicz K.: Eur. J. Med. Chem. 39, 1013
(2004).
19. Handzlik J., Maciπg D., Kubacka M., Mogilski
S., Filipek B., Stadnicka K., KieÊ-Kononowicz
K.: Bioorg. Med. Chem. 16, 5982 (2008).
20. Handzlik J., SzymaÒska E., NÍdza K., Kubacka
M., Siwek A., Mogilski S., Filipek B., KieÊ-
Kononowicz K.: Bioorg. Med. Chem. 19, 1349
(2011).
21. Spengler G., Evaristo M., Handzlik J., Serly J.,
Moln·r J., Viveiros M, KieÊ-Kononowicz K.,
Amaral L.: Anticancer Res. 30, 4867 (2010).
22. Pastan I., Gottesman M.M., Ueda K., Lovelace
E., Rutherford A.V, Willingham M.C.: Proc.
Natl. Acad. Sci. USA 85, 4486, (1988). 
23. Choi K., Frommel T.O., Stern R.K., Perez C.F.,
Kriegler M., Tsuruo T., Roninson I.B.: Proc.
Natl. Acad. Sci. USA 88, 7386, (1991).
24. Gyemant N., Tanaka M., Molnar P., Deli J.,
Mandoky L., Molnar J : Anticancer Res. 26,
367 (2006).
Received: 21. 10. 2011
